xRead - Globus and Chronic Cough (April 2024)

Wamkpah et al.

Page 21

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE I. # Patients

Secondary outcome measure(s)

Sputum examination

Sputum examination Serum examination CQLQ

Exhaled NO and CO PFTs

Citric acid cough challenge

Cough severity VAS LCQ

Cough VAS

Capsaicin cough challenge

Sputum neutrophil count

Rate of cough control LCQ

Primary

outcome

measure

2 weeks Cough

discomfort VAS

2 weeks Cough severity VAS

10 days Reduction in cough

frequency and severity

4 weeks LCQ

Number of

patients with sedation

2 weeks Cough

symptom diary

12 weeks 24-hr cough frequency

(coughs/hr)

8 weeks Cough

symptom score

Treatment duration

cetirizine 10 mg daily Corticosteroid: oral prednisone 25 mg daily ×1 week +

200 μg/inhalation BID PPI and antimotility agent omeprazole 20 mg BID +

Bronchodilator

and antihistamine

Comparator

intervention (n patients)

Placebo inhaler, 1

inhalation BID (24)

Placebo inhaler, 1 inhalation BID

Codeine/guaifenesin

100 mg/5 mL, 10 mL q6hr (13)

Placebo oral tablet BID

Placebo inhaler, 2

inhalation TID (20)

Placebo oral tablet daily (15)

Methoxyphenamine 2 capsules TID +

inhaled budesonide

diprophylline 200 mg TID + cetirizine 10 mg daily Corticosteroid: oral

Inhaled corticosteroid: budesonide 400 μg/

59 Inhaled corticosteroid: fluticasone 500 μg/ inhalation BID E: 54.6 C: 49.7

Tricyclic antidepressant:

RCT post hoc analysis of AEs 27; 27(9/18) 55 Opioid analgesic:

Inhaled corticosteroid:

Macrolide antibiotic:

Bronchodilator

and antihistamine:

PPI and antimotility agent: omeprazole 20 mg BID + domperidone 10 mg TID (120)

Experimental

intervention (n patients)

inhalation BID (24)

amitriptyline 10 mg qHS (15)

morphine 5 mg BID

beclomethasone 500 μg/ inhalation TID (44)

erythromycin 250 mg daily (15)

prednisone 25 mg daily ×1 week + inhaled budesonide 200 μg/inhalation BID

Average age in

years

E: 43

C: 47

E: 46

C: 50

E: 63

C: 61

E: 45

C: 45

enrolled;

completed therapy

(males/

females)

(16/28)

93; 88

(32/57)

(13/15)

(22/42)

(6/24)

(93/147)

Characteristics of Included Studies, Stratified by Intervention Type: Medical Therapy, Speech Therapy, Procedural Therapy. Author or clinical trial number (year) Location Study design Medical therapy Pizzichini et al (1999) Hamilton, Ontario, CAN Parallel RCT 48; 44 Chaudhuri et al (2004) Glasgow, Scotland, UK Crossover RCT Jeyakumar et al (2006) Cleveland, OH, USA Parallel RCT 28; 28 Morice et al (2007) East Yorkshire, England, UK Crossover Dickinson et al (2014) Ribeiro et al (2007) Sao Paulo, Brazil Parallel RCT 64; 64 Yousaf et al (2009) Leicester, England, UK Parallel RCT 30; 28 Qiu et al (2010) Shanghai, China Parallel RCT 240; 214

Laryngoscope . Author manuscript; available in PMC 2022 January 01.